Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience
Autor: | Steven M. Devine, Christina Matthews, Marcin Puto, Junan Li, Yvonne A. Efebera, Filiz Yucebay, Julianna Roddy, Basem M. William, Samantha Jaglowski, Don M. Benson, Sam Penza, Sumithira Vasu, Leslie A. Andritsos |
---|---|
Rok vydání: | 2019 |
Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Drug Resistance Graft vs Host Disease Kaplan-Meier Estimate Antibodies Monoclonal Humanized Single Center Gastroenterology Young Adult 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine First line therapy Tocilizumab immune system diseases hemic and lymphatic diseases Internal medicine Acute graft versus host disease Humans Transplantation Homologous Medicine Glucocorticoids Aged Retrospective Studies integumentary system business.industry Hematopoietic Stem Cell Transplantation Hematology Middle Aged Allografts Treatment Outcome surgical procedures operative Oncology chemistry Hematologic Neoplasms 030220 oncology & carcinogenesis Acute Disease Disease Progression Female Stem cell Steroid refractory business Complication Immunosuppressive Agents 030215 immunology |
Zdroj: | Leukemia & Lymphoma. 60:2223-2229 |
ISSN: | 1029-2403 1042-8194 |
Popis: | Acute graft-versus-host-disease (aGVHD) is a complication after allogeneic stem cell transplant. After the failure of treatment with high dose corticosteroids, steroid-refractory aGVHD (SR aGVHD) is associated with high rates of mortality. Tocilizumab has evidence of activity in SR aGVHD. For patients ineligible for trials, the OSU James Comprehensive Cancer Center has been utilizing tocilizumab as first-line therapy for SR aGVHD. We retrospectively report on 15 patients who received tocilizumab. aGVHD grading and responses were based on consensus criteria. Median age at transplant was 49 years. Median time to tocilizumab administration was 9 days (range, 3-16). Six patients had complete responses (40%) with a resolution of aGVHD. From the last contact, median overall survival for responders was not yet reached vs. 31 days for non-responders ( |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |